ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.856,48
-0,77%
S&P 500
5.827,04
-1,54%
US Dollar vs BRL
6,12417
0,00%
Bitcoin
94.456,04
-0,26%
Brent Oil
79,285
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. DiaMedica Therapeutics Inc (DMAC)

  7. DiaMedica Therapeutics Inc (DMAC) Notícias

DMAC

DiaMedica Therapeutics (DMAC)

DiaMedica Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DMAC
DataHoraFonteTítuloCódigoCompanhia
03/01/202518:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202418:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202418:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DMACDiaMedica Therapeutics Inc
19/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DMACDiaMedica Therapeutics Inc
18/07/202418:28Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:DMACDiaMedica Therapeutics Inc
10/07/202417:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:DMACDiaMedica Therapeutics Inc
08/07/202418:23Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:DMACDiaMedica Therapeutics Inc
01/07/202409:00Business WireDiaMedica Therapeutics Announces Closing of $11.8 Million Private PlacementNASDAQ:DMACDiaMedica Therapeutics Inc
26/06/202409:15Business WireDiaMedica Therapeutics Announces $11.8 Million Private PlacementNASDAQ:DMACDiaMedica Therapeutics Inc
26/06/202409:00Business Wire DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into PreeclampsiaNASDAQ:DMACDiaMedica Therapeutics Inc
24/05/202417:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DMACDiaMedica Therapeutics Inc
08/05/202417:30Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
02/05/202409:55Business WireDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024NASDAQ:DMACDiaMedica Therapeutics Inc
17/04/202417:08Business WireDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeNASDAQ:DMACDiaMedica Therapeutics Inc
19/03/202417:15Business WireDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
29/01/202418:13Business WireDiaMedica Therapeutics Announces Poster Presentation at International Stroke ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
23/01/202418:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DMACDiaMedica Therapeutics Inc
22/01/202410:23Business WireDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
13/11/202318:28Business WireDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
09/11/202310:25Business WireDiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
06/11/202310:23Business WireDiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
12/09/202309:13Business WireDiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology OfficerNASDAQ:DMACDiaMedica Therapeutics Inc
06/09/202309:35Business WireDiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
14/08/202317:13Business WireDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial ResultsNASDAQ:DMACDiaMedica Therapeutics Inc
08/08/202309:32Business WireDiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023NASDAQ:DMACDiaMedica Therapeutics Inc
18/07/202309:30Business WireDiaMedica Therapeutics to Attend the American Academy of Neurology Summer ConferenceNASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202317:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DMACDiaMedica Therapeutics Inc
27/06/202317:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:DMACDiaMedica Therapeutics Inc
26/06/202309:30Business WireDiaMedica Therapeutics Announces Closing of $37.5 Million Private PlacementNASDAQ:DMACDiaMedica Therapeutics Inc
23/06/202318:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DMACDiaMedica Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DMAC

Seu Histórico Recente

USOTC
MGDDY
Michelin Compagnie Gener... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados